Immunotherapy for Lung Cancer.
Immune evasion is recognized as a key strategy for cancer survival and progression. Hence, various approaches to restore antitumor immune responses are currently being investigated. In particular, agents targeting immune checkpoints, such as the cytotoxic T-lymphocyte-associated antigen-4 receptor and programmed death-1 receptor, have shown potential for improving tumor responses and survival in lung cancer patients. With the first immunomodulating agents having been approved for treatment of selected lung cancer patients, there are high expectations that treatment outcomes may be improved with the incorporation of immunotherapies into the various treatment cascades.
Department of Thoracic Oncology, Fachklinik Gauting, Member of the German Center for Lung Research (DZL), Gauting, Germany.
Niels
N
Reinmuth
Martin
M
Reck
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000276:immunology; D019317:Evidence-Based Medicine; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000639:trends*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines